DBV Technologies Announces Financial Calendar 2017

09.01.17 07:30
<strong>DBV Technologies</strong> Announces Financial Calendar 2017
Press Release

Montrouge, France, January 9, 2017

DBV Technologies Announces Financial Calendar 2017

DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), today announced its 2017 financial calendar[1] :

  • February 20, 2017 - cash position December 31, 2016
  • March 15, 2017 - full-year 2016 results
  • April 28, 2017 - first three months 2017 cash position
  • June 15, 2017 - Annual General Meeting
  • July 28, 2017 - first-half 2017 results
  • October 31, 2017 - nine months 2017 cash position

The Company will issue the above financial results before the Euronext Paris market opens, respectively.

About DBV Technologies 

DBV Technologies is developing Viaskin®, a proprietary technology platform with broad potential applications in immunotherapy. Viaskin is based on epicutaneous immunotherapy, or EPIT®, DBV's method of delivering biologically active compounds to the immune system through intact skin. With this new class of self-administered and non-invasive product candidates, the company is dedicated to safely transforming the care of food allergic patients, for whom there are no approved treatments. DBV's food allergies programs include ongoing clinical trials of Viaskin Peanut and Viaskin Milk, and preclinical development of Viaskin Egg. DBV is also pursuing a human proof-of-concept clinical study of Viaskin Milk for the treatment of Eosinophilic Esophagitis, and exploring potential applications of its platform in vaccines and other immune diseases.

DBV Technologies has global headquarters in Montrouge, France and New York, NY as well as New Jersey, CT. Company shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345), part of the SBF120 index, and traded on the Nasdaq Global Select Market in the form of American Depositary Shares (each representing one-half of one ordinary share) (Ticker: DBVT). For more information on DBV Technologies, please visit our website: www.dbv-technologies.com

Forward Looking Statements

This press release may contain forward-looking statements and estimates. These forward-looking statements and estimates are not promises or guarantees and involve substantial risks and uncertainties. At this stage, the products of the Company have not been authorized for sale in any country. Among the factors that could cause actual results to differ materially from those described or projected herein include uncertainties associated generally with research and development, clinical trials and related regulatory reviews and approvals, the risk that historical preclinical results may not be predictive of future clinical trial results, and the risk that historical clinical trial results may not be predictive of future trial results. A further list and description of these risks, uncertainties and other risks can be found in the Company's regulatory filings with the French Autorité des Marchés Financiers, the Company's Securities and Exchange Commission filings and reports, including in the Company's Annual Report on Form 20-F for the year ended December 31, 2015 and future filings and reports by the Company.  Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements and estimates, which speak only as of the date hereof. Other than as required by applicable law, DBV Technologies undertakes no obligation to update or revise the information contained in this Press Release.

DBV Technologies Contact

Susanna Mesa

Senior Vice President, Strategy

+1 212-271-0861


Media Contact Europe

Caroline Carmagnol, Alize RP, Relations Presse

+33 (0)6 64 18 99 59 


[1] The financial calendar above is provided for informational purposes only. The dates are subject to change and will be regularly updated by the Company as it deems necessary. The Company's current financial calendar can be found on its corporate website.

PDF Version

This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: DBV Technologies via Globenewswire


Breaking News

Kurs- und weitere Informationen zum Thema:

DBV Technologies

Aktuelle Diskussionen zum Thema:

Aktuelle Nachrichten zum Unternehmen:

Alle Nachrichten zum Unternehmen

Aktuelle Analysen zu den Unternehmen:

DBV Technologies
Weitere Meldungen
09.01 Outotec and Outokumpu sett.
09.01 The European Patent Office.
09.01 Ahold Delhaize commences .
09.01 Cancellation of Extraordinary.
09.01 TGS Q4 2016 Update and .
09.01 SOITEC : Launch of the rev.
09.01 DBV Technologies Announce.
09.01 Addex ADX71441 Demonstr.
09.01 Takeda notifies 4.48% share.
09.01 DNO Makes Cretaceous Oil .
08.01 Ad hoc: Die Geschäftsführu.
07.01 Ad hoc: Fresenius Medical C.
06.01 Ad hoc: Pütz Vermögensver.
06.01 Ad hoc: Pelikan Aktiengesel.
06.01 Ad hoc: Travel24.com AG: .
06.01 Akastor ASA: Akastor com.
06.01 Ad hoc: Medios AG: Vollstä.
06.01 EQS-Adhoc: Pax Anlage AG.
06.01 Sanofi and Regeneron to A.
05.01 Ad hoc: USU Software AG.
05.01 Dassault Aviation: Order inta.
05.01 Songa Offshore SE : Conve.
05.01 Eastman Schedules Fourth-Q.
05.01 Talvivaara Mining Company .
05.01 VALLOUREC : Paris-Orly A.
05.01 Ad hoc: RENÉ LEZARD Mo.
05.01 Ad hoc: 3W Power S.A.: G.

Welche Social Networks nutzen Sie meistens?
Linked in

Stimmen: 43634 , Ergebnis

Status: nicht eingeloggt

Registrieren | Passwort vergessen?
Im Bereich Nachrichten:
Commerzbank: Es wird immer dramatischer!
Experte: Stefan Hofmann, STOCK-WORLD
Gold: Markiert Fünf-Monats-...
Jürgen Sterzbach, boerse-daily.de (09:55)
Experte: Jürgen Sterzbach, boerse-daily.de
DAX Analyse ...
X-markets Team, Deutsche Bank (09:46)
Experte: X-markets Team, Deutsche Bank
Commerzbank - Kursziel ...
Christian Zoller, www.boerse-daily.de (09:37)
Experte: Christian Zoller, www.boerse-daily.de
VW – 38 Prozent möglich
Feingold-Research, (09:29)
Experte: Feingold-Research,
Deutsche Telekom: Wo ...
Robert Sasse, (09:16)
Experte: Robert Sasse,
RavenQuest schließt ...
Jörg Schulte, JS-Research (09:07)
Experte: Jörg Schulte, JS-Research
Verbund-Aktienanleihen mit ...
Walter Kozubek, (08:32)
Experte: Walter Kozubek,
Intel: Die Vorzeichen waren ...
Volker Gelfarth, (08:25)
Experte: Volker Gelfarth,
Den Fahrverboten kontern
Ingrid Heinritzi, (08:20)
Experte: Ingrid Heinritzi,
Dow Jones Index: Ausbruch ...
S. Feuerstein, Hebelzertifikate-Trader (08:04)
Experte: S. Feuerstein, Hebelzertifikate-Trader
UniDevice: Erfolg im ...
Holger Steffen, (07:23)
Experte: Holger Steffen,
Gold - Wir werden den ...
Philip Hopf, Hopf Klinkmüller Capital. (18.12.18)
Experte: Philip Hopf, Hopf Klinkmüller Capital Management K.
Niquet's World
Neues vom Portal
Die Geldanlage: Eine kleine Einführung
Letzte Börsen-Meldung
Letzte Börsen-Analyse
Top-Klicks News
Top-Klicks Analysen